Silence Therapeutics plc (SLN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Silence Therapeutics reported revenue of $559,000, down 98.7% from $43.3M the year before. Net income was -$88.6M (a -15851.9% net margin), or -$0.63 per diluted share. Gross margin was 61.5% and operating margin was -16292.8%. Operating activities generated -$62.3M of cash, leaving -$62.4M of free cash flow. At fiscal year end, Silence Therapeutics held $131.4M in total assets against $69.1M in total liabilities, including $11.3M of cash and equivalents.
Open the full interactive Silence Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Silence Therapeutics Key Stats
| Share Price | $8.87 |
|---|---|
| Market Cap | $419.0M |
| Revenue YoY Growth | -98.7% |
| 52-Week Range | $4.30 – $15.43 |
| Shares Outstanding | 141.7 million (basic, 2026 Q2) |
Silence Therapeutics Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $43.3M | $559,000 |
| Cost of Goods Sold | $11.8M | $215,000 |
| Gross Profit | $31.4M | $344,000 |
| Operating Income | -$63.3M | -$91.1M |
| Pre-Tax Income | -$44.5M | -$88.6M |
| Income Tax | $845,000 | $11,000 |
| Net Income | -$45.3M | -$88.6M |
| Diluted EPS | -$0.33 | -$0.63 |
Silence Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $159,000 | $34,000 | $422,000 | $0 |
| Net Income | -$21.0M | -$11.8M | -$15.0M | -$12.3M |
| Diluted EPS | -$0.15 | -$0.08 | -$0.11 | -$0.09 |
Silence Therapeutics Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $121.3M | $11.3M |
| Current Assets | $187.4M | $118.7M |
| Total Assets | $202.6M | $131.4M |
| Current Liabilities | $16.8M | $13.6M |
| Total Liabilities | $68.6M | $69.1M |
| Shareholders' Equity | $134.0M | $62.3M |
Silence Therapeutics Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$67.6M | -$62.3M |
| Cash From Investing | -$22.0M | -$48.0M |
| Cash From Financing | $142.1M | $15,000 |
| Free Cash Flow | -$67.8M | -$62.4M |
Figures from Silence Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Silence Therapeutics financials page for every line item.
Silence Therapeutics Company Profile
| Ticker | SLN |
|---|---|
| Exchange | Nasdaq, OTC |
| Industry | Pharmaceutical Preparations |
| Headquarters | London |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001479615 |
Frequently Asked Questions
What was Silence Therapeutics' revenue in fiscal 2025?
Silence Therapeutics (SLN) reported revenue of $559,000 for fiscal 2025.
What was Silence Therapeutics' net income in fiscal 2025?
Silence Therapeutics reported net income of -$88.6M for fiscal 2025.
What was Silence Therapeutics' earnings per share (EPS) in fiscal 2025?
Silence Therapeutics' diluted EPS was -$0.63 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Silence Therapeutics generate in fiscal 2025?
Silence Therapeutics generated -$62.4M of free cash flow in fiscal 2025.
What was Silence Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Silence Therapeutics reported revenue of $0.
How many shares of Silence Therapeutics are outstanding?
Silence Therapeutics reported a weighted average of 141.7 million basic shares outstanding in 2026 Q2.
What is Silence Therapeutics' market cap?
Based on its latest closing price, Silence Therapeutics (SLN) has a market capitalization of about $419.0M.
Where is Silence Therapeutics headquartered?
Silence Therapeutics lists its business address in London in its SEC filings.